trending Market Intelligence /marketintelligence/en/news-insights/trending/gbi4M7gvP6JRgYbcSGfgHg2 content esgSubNav
In This List

Johnson & Johnson ends deals talks with Actelion

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Johnson & Johnson ends deals talks with Actelion

Johnson & Johnson ended discussions with Actelion Pharmaceuticals Ltd. regarding a potential transaction as it was not able to reach an agreement that would create adequate value for its shareholders.

Bloomberg News previously reported that Actelion rejected Johnson & Johnson's initial offer, which was priced at CHF246 per share, valuing Actelion at $26 billion.